Clinical Hold of Viking's (VKTX) VK0214 Trial is Immaterial, Bull Thesis is Based on VK2809 in NASH, Buy the Weakness - Truist Securities
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $28.00 price target on Viking Therapeutic (NASDAQ: VKTX), following announcement ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
